Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Drug resistance in cancer: molecular evolution and compensatory proliferation
Linnaeus University, Faculty of Health and Life Sciences, Department of Chemistry and Biomedical Sciences. (CCBG)ORCID iD: 0000-0001-8696-3104
2016 (English)In: OncoTarget, ISSN 1949-2553, E-ISSN 1949-2553, Vol. 7, no 11, 11746-11755 p.Article in journal (Refereed) Published
Abstract [en]

Targeted therapies have revolutionized cancer treatment. Unfortunately, their success is limited due to the development of drug resistance within the tumor, which is an evolutionary process. Understanding how drug resistance evolves is a prerequisite to a better success of targeted therapies. Resistance is usually explained as a response to evolutionary pressure imposed by treatment. Thus, evolutionary understanding can and should be used in the design and treatment of cancer. In this article, drug-resistance to targeted therapies is reviewed from an evolutionary standpoint. The concept of apoptosis-induced compensatory proliferation (AICP) is developed. It is shown that AICP helps to explain some of the phenomena that are observed experimentally in cancers. Finally, potential drug targets are suggested in light of AICP.

Place, publisher, year, edition, pages
2016. Vol. 7, no 11, 11746-11755 p.
Keyword [en]
nearly neutral theory, neoplasm, leukemia, bladder cancer, somatic mutations
National Category
Cancer and Oncology
Research subject
Natural Science, Biomedical Sciences
Identifiers
URN: urn:nbn:se:lnu:diva-49818DOI: 10.18632/oncotarget.7459ISI: 000375679600002PubMedID: 26909596Scopus ID: 2-s2.0-84962798373OAI: oai:DiVA.org:lnu-49818DiVA: diva2:904119
Funder
Swedish Research Council, VR 2014-4406Swedish Cancer Society, CAN 2015/387
Available from: 2016-02-18 Created: 2016-02-18 Last updated: 2017-11-30Bibliographically approved

Open Access in DiVA

fulltext(2208 kB)144 downloads
File information
File name FULLTEXT01.pdfFile size 2208 kBChecksum SHA-512
a09f2fdfea3decf458c454090b1d7a9f2a55b202035842f580d85c1a2d4bacf2b64623e0b696bfce78bc60724598218a627f3a4cf0ea8996da97a4cfae915691
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Friedman, Ran
By organisation
Department of Chemistry and Biomedical Sciences
In the same journal
OncoTarget
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 144 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 553 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf